SCHEMBL14735401

SCHEMBL14735401

COc1ccc2c(c1C(C)N1CCN(C(=O)OC(C)(C)C)CC1)OCC2=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.37
▸ STS P08842 1/20 0.37
▸ F13A1 P00488 1/20 0.36
▸ TGM2 P21980 1/20 0.36
▸ TGM1 P22735 1/20 0.36
▸ HTT P42858 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ PDE4B Q07343 4/20 0.36
▸ PDE11A Q9HCR9 1/20 0.36
▸ PDE10A Q9Y233 1/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ CFTR P13569 1/20 0.36
▸ SETD7 Q8WTS6 1/20 0.36
▸ PDE4A P27815 2/20 0.36
▸ PDE4C Q08493 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18864077 0.89 ABCB1 (0.35) ALDH1A1HTTNPC1MAPTMAPK1
SCHEMBL14735105 0.88 PSMB5 (0.40) ALDH1A1HTTNPC1MAPTMAPK1
SCHEMBL18864150 0.86 TBK1 (0.39) ALDH1A1HTTNPC1MAPTMAPK1
SCHEMBL18864094 0.85 ABCB1 (0.39) ALDH1A1STSF13A1TGM2TGM1
SCHEMBL14734906 0.79 CHRM2 (0.41) ALDH1A1STSF13A1TGM2TGM1
SCHEMBL14735244 0.78 MEN1 (0.37) ALDH1A1STSF13A1TGM2TGM1
SCHEMBL14735473 0.78 MEN1 (0.47) ALDH1A1STSHTTMAPTPDE4B
SCHEMBL18864111 0.77 CHRM2 (0.44) ALDH1A1STSF13A1TGM2TGM1
SCHEMBL14735273 0.76 PDE4B (0.50) ALDH1A1STSPDE4BMEN1KMT2A
SCHEMBL14734959 0.76 MMP2 (0.41) ALDH1A1STSF13A1TGM2TGM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170145005-A1 KINASE INHIBITOR THE UNIVERSITY OF TOKYO (JP) 2017-05-25 — — US disclosed
US-20170145005-A1 KINASE INHIBITOR THE UNIVERSITY OF TOKYO (JP) 2017-05-25 — — US disclosed
EP-2565192-B9 ANTICANCER AGENT UNIV TOKYO (JP) 2015-11-25 — — EP disclosed
US-9156827-B2 Anticancer agent THE UNIVERSITY OF TOKYO (JP) 2015-10-13 — — US disclosed
EP-2565192-B1 ANTICANCER AGENT UNIV TOKYO (JP) 2015-08-12 — — EP disclosed
US-20130102776-A1 ANTICANCER AGENT RIKEN (JP) 2013-04-25 — — US disclosed
EP-2565192-A1 ANTICANCER AGENT The University of Tokyo (JP) 2013-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170145005-A1 KINASE INHIBITOR PIM3, PIM1, PIM2 ALDH1A1 2231/4885STS 4000/4885F13A1 4026/4885
US-20130102776-A1 ANTICANCER AGENT PIM1, PIM3, PIM2 ALDH1A1 1194/4885STS 3492/4885F13A1 3297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback